Vaccine for treatment of tautopathy

Patent metadata

Field	Value
Publication number	US-8945576-B2
Application number	US-201113520968-A
Country	US
Kind code	B2
Filing date	Jan 11, 2011
Priority date	Jan 8, 2010
Publication date	Feb 3, 2015
Grant date	Feb 3, 2015

Abstract

This invention relates to a vaccine for preventing or treating tautopathy, comprising a vector, as an active ingredient, comprising a nucleic acid encoding a mutant tau protein linked to a secretion signal sequence, wherein the vaccine is capable of inducing an antibody against an (optionally phosphorylated) tau protein in a subject in a more sustained manner compared with a case where the mutant tau protein is administered directly.

First claim

The invention claimed is:

1. A vaccine for treating tauopathy dementia, comprising a vector as an active ingredient,
wherein the vector comprises a nucleic acid encoding a full length mutant tau protein linked to a secretory signal sequence,
wherein the full length mutant tau protein comprises a substitution mutation of an amino acid residue, P301S, at a position 301 of the amino acid sequence of SEQ ID NO: 1 of a tau protein, and
wherein the vector is a Sendai virus vector and is capable of inducing an antibody to the full length mutant tau protein in a subject in a sustained manner and is capable of reacting with phosphorylated tau protein present in the hippocampus of the subject.

2. The vaccine according to claim 1 , wherein the secretory signal sequence is a signal sequence of amyloid precursor protein or a signal sequence of CD59.

3. The vaccine according to claim 1 , wherein the vector is a Sendai virus vector in which F gene is deleted.

4. The vaccine according to claim 1 , wherein the vaccine is formulated for intranasal administration.

5. The vaccine according to claim 1 , wherein the vaccine has an effect of improving at least one symptom of abnormal social interaction, abnormal anxiety-like behavior, and impaired memory in a subject.

6. The vaccine according to claim 1 , wherein the vaccine has an effect of activating microglia in the brain of a subject and thereby suppressing the accumulation of the mutant tau protein.

7. The vaccine according to claim 1 , wherein the vector is capable of inducing an antibody to phosphorylated mutant tau protein.

Assignees

• Inoue Haruhisa
• Takeuchi Hiroki
• Takahashi Ryosuke
• Higuchi Makoto
• Ji Bin
• Suhara Tetsuya
• Univ Kyoto
• Nat Inst Radiolog

Inventors

• Inoue Haruhisa
• Takeuchi Hiroki
• Takahashi Ryosuke
• Higuchi Makoto
• Ji Bin
• Suhara Tetsuya

Classifications

• A61K39/0005

  Vertebrate antigens (from snakes A61K39/38) · CPC title

• C12N2799/021

  for the expression of a heterologous nucleic acid · CPC title

• C07K2319/02

  containing a signal sequence · CPC title

• A61K2039/53

  DNA (RNA) vaccination · CPC title

• A61P25/14

  for treating abnormal movements, e.g. chorea, dyskinesia · CPC title